Empfehlungen zur medikamentösen Therapie der Osteoporose

Für die medikamentöse Therapie der postmenopausalen Osteoporose und der männlichen Osteoporose stehen mehrere Therapiemöglichkeiten vom Evidenzgrad A zur Verfügung: Bisphosphonate, Selektive Östrogen Rezeptor Modulatoren (Raloxifen), Strontiumranelat und Teriparatid. Die Behandlung sollte schnellstmöglich einsetzen und bis zur Neuevaluation über 3-5 Jahre erfolgen. Allgemein skelettprotektive Maßnahmen (Sturzvermeidung, Physiotherapie, Calcium-, Vitamin D-Versorgung) sollen begleitend durchgeführt werden.

Medical treatment of postmenopausal osteoporosis and osteoporosis of men includes drugs fulfilling evidence based medicine criteria (class A): bisphosphonates, raloxifene, strontium ranelate and teriparatide. Medical treatment should be started imediately and continued over 3-5 years until reavaluation of fracture risk of the individual patient. Risk of falls should be minimized and calcium and vitamin D supply must be adequate.

Literatur

• 1 Orwoll E, Ettinger M, Weiss S. et al. . Alendronate for the treatment of osteoporosis in men.  N Engl J Med. 2000;  343 604-610
• 2 Mc Clung, Geusens P, Miller PD. et al. . Hip Intervention Program Study Group. Effect of risedronate on hip fracture in elderly women. Hip Intervention Study Group.  N Engl J Med. 2001;  344 333-340
• 3 Chesnut CH III, Skag A, Christiansen C. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.  J Bone Mineral Res. 2004;  19 1241-1249
• 4 Ettinger B, Black DM, Milack BH. et al. . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.  JAMA. 1999;  282 637-645
• 5 Neer RM, Arnaud CD, Zanchetta JR. et al. . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.  N Engl J Med. 2001;  344 1434-1441
• 6 Lindsay R, Scheele WH, Neer R. et al. . Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.  Arch Intern Med. 2004;  164 2024-2030
• 7 Meunier PJ, Roux C, Seeman E. et al. . The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.  N Engl J Med. 2004;  350 459-468
• 8 Richy F, Ethgen O, Bruyere O. Efficacy of alphacalcidol and calcitriol in primary and corticoid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.  Osteopos Int. 2004;  15 301-310
• 9 Cauley JA, Chen Z, Cummings SR. Women's Health Initiative Investigators. Effects of Estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.  JAMA. 2003;  290 1729-1738
• 10 Kanis JA, Johansson H, Oden A. et al. . A meta-analysis of prior corticosteroid use and fracture risk.  J Bone Miner Res. 2004;  19 893-899

Anschrift des Verfassers